Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response

References

• Powers ET, Kelly JW. From uncovering the mechanism of transthyretin aggregation to the drug tafamidis for ameliorating neurodegeneration and cardiomyopathy. In Smith RA, Kaspar BK, Svendsen CN, editors. Neurotherapeutics in the era of translational medicine. London: Academic Press; 2021. p. 65–103.
   Google Scholar
• Jacobsson B, Collins VP, Grimelius L, et al. Transthyretin immunoreactivity in human and porcine liver, choroid plexus, and pancreatic islets. J Histochem Cytochem. 1989;37(1):31–37.
   PubMed Web of Science ®Google Scholar
• Schreiber G. The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis. J Endocrinol. 2002;175(1):61–73.
   PubMed Web of Science ®Google Scholar
• Monaco HL. The transthyretin-retinol-binding protein complex. Biochim Biophys Acta. 2000;1482(1-2):65–72.
   PubMedGoogle Scholar
• Wojtczak A, Cody V, Luft JR, et al. Structures of human transthyretin complexed with thyroxine at 2.0 Å resolution and 3',5'-dinitro-N-acetyl-L-thyronine at 2.2 a resolution. Acta Crystallogr D Biol Crystallogr. 1996;52(Pt 4):758–765.
   PubMedGoogle Scholar
• Rappley I, Monteiro C, Novais M, et al. Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry. 2014;53(12):1993–2006.
   PubMed Web of Science ®Google Scholar
• Nelson LT, Paxman RJ, Xu J, et al. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma. Amyloid. 2021;28(1):24–29.
   PubMed Web of Science ®Google Scholar
• Wang D, Liem DA, Lau E, et al. Characterization of human plasma proteome dynamics using deuterium oxide. Proteomics Clin Appl. 2014;8(7-8):610–619.
   PubMed Web of Science ®Google Scholar
• Adams D, Koike H, Slama M, et al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387–404.
   PubMed Web of Science ®Google Scholar
• Ruberg FL, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872–2891.
   PubMed Web of Science ®Google Scholar
• Ihse E, Ybo A, Suhr O, et al. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol. 2008;216(2):253–261.
   PubMed Web of Science ®Google Scholar
• Reixach N, Deechongkit S, Jiang X, et al. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA. 2004;101(9):2817–2822.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Wiese S, Adak V, et al. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. Nat Commun. 2019;10(1):5008.
   PubMedGoogle Scholar
• Schonhoft JD, Monteiro C, Plate L, et al. Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. Sci Transl Med. 2017;9(407):eaam7621.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Duarte A, Valdés-Ferrer SI, Cantú-Brito C. Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review. Clin Auton Res. 2019;29(Suppl 1):1–9.
   PubMed Web of Science ®Google Scholar
• Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829–837.
   PubMed Web of Science ®Google Scholar
• Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99(9):1847–1854.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
   PubMed Web of Science ®Google Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–792.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Sultan MB, Rapezzi C. Tafamidis for transthyretin amyloid cardiomyopathy. N Engl J Med. 2019;380(2):196–197.
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–2667.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016.
   PubMed Web of Science ®Google Scholar
• Hammarstrom P, Wiseman RL, Powers ET, et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003;299(5607):713–716.
   PubMed Web of Science ®Google Scholar
• Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109(24):9629–9634.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006;13(4):236–249.
   PubMed Web of Science ®Google Scholar
• Benson MD, Dwulet FE. Prealbumin and retinol binding protein serum concentrations in the Indiana type hereditary amyloidosis. Arthritis Rheum. 1983;26(12):1493–1498.
   PubMedGoogle Scholar
• Saraiva MJ, Costa PP, Goodman DS. Studies on plasma transthyretin (prealbumin) in familial amyloidotic polyneuropathy, portuguese type. J Lab Clin Med. 1983;102(4):590–603.
   PubMed Web of Science ®Google Scholar
• Monteiro C, Mesgazardeh JS, Anselmo J, et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. 2019;4(12):e126526.
   PubMed Web of Science ®Google Scholar
• Hanson JLS, Arvanitis M, Koch CM, et al. Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin. Circ Heart Fail. 2018;11(2):e004000.
   PubMed Web of Science ®Google Scholar
• Greve AM, Christoffersen M, Frikke-Schmidt R, et al. Association of low plasma transthyretin concentration with risk of heart failure in the general population. JAMA Cardiol. 2021;6(3):258–266.
   PubMed Web of Science ®Google Scholar
• Saith SE, Gamino D, Teruya S, et al. Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis. Amyloid. 2021;28(4):267–268.
   PubMed Web of Science ®Google Scholar
• Choi S, Ong DS, Kelly JW. A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate. J Am Chem Soc. 2010;132(45):16043–16051.
   PubMed Web of Science ®Google Scholar
• Jiang X, Labaudiniere R, Buxbaum JN, et al. A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Proc Natl Acad Sci U S A. 2021;118(9):e2016072118.
   PubMed Web of Science ®Google Scholar
• Ritchie RF, Palomaki GE, Neveux LM, et al. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal. 1999;13(6):273–279.
   PubMed Web of Science ®Google Scholar
• Judge DP, Heitner SB, Falk RH, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74(3):285–295.
   PubMed Web of Science ®Google Scholar
• Falk RH, Haddad M, Walker CR, et al. Effect of tafamidis on serum transthyretin levels in non-trial patients with transthyretin amyloid cardiomyopathy. JACC CardioOncol. 2021;3(4):580–586.
   PubMedGoogle Scholar
• Lockwood PA, Le VH, O'Gorman MT, et al. The bioequivalence of tafamidis 61-mg free acid capsules and tafamidis meglumine 4 x 20-mg capsules in healthy volunteers. Clin Pharmacol Drug Dev. 2020;9(7):849–854.
   PubMed Web of Science ®Google Scholar
• Wiseman RL, Johnson SM, Kelker MS, et al. Kinetic stabilization of an oligomeric protein by a single ligand binding event. J Am Chem Soc. 2005;127(15):5540–5551.
   PubMed Web of Science ®Google Scholar
• Rosen HN, Moses AC, Murrell JR, et al. Thyroxine interactions with transthyretin: a comparison of 10 different naturally occurring human transthyretin variants. J Clin Endocrinol Metab. 1993;77(2):370–374.
   PubMed Web of Science ®Google Scholar
• Gundapaneni BK, Sultan MB, Keohane DJ, et al. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2018;25(3):464–468.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Genereux JC, Suh EH, et al. Endoplasmic reticulum proteostasis influences the oligomeric state of an amyloidogenic protein secreted from mammalian cells. Cell Chem Biol. 2016;23(10):1282–1293.
   PubMed Web of Science ®Google Scholar
• Parenti G, Andria G, Valenzano KJ. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther. 2015;23(7):1138–1148.
   PubMed Web of Science ®Google Scholar
• Fox JC, Hellawell JL, Rao S, et al. First-in-human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: a phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers. Clin Pharmacol Drug Dev. 2020;9(1):115–129.
   PubMed Web of Science ®Google Scholar
• Kurian SM, Novais M, Whisenant T, et al. Peripheral blood cell gene expression diagnostic for identifying symptomatic transthyretin amyloidosis patients: male and female specific signatures. Theranostics. 2016;6(11):1792–1809.
   PubMed Web of Science ®Google Scholar
• Azevedo EP, Guimaraes-Costa AB, Bandeira-Melo C, et al. Inflammatory profiling of patients with familial amyloid polyneuropathy. BMC Neurol. 2019;19(1):146.
   PubMedGoogle Scholar
• Lemos C, Coelho T, Alves-Ferreira M, et al. Overcoming artefact: anticipation in 284 portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M. J Neurol Neurosurg Psychiatry. 2014;85(3):326–330.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Davies JL, Litchy WJ, et al. Longitudinal assessment of diabetic polyneuropathy using a composite score in the rochester diabetic neuropathy study cohort. Neurology. 1997;49(1):229–239.
   PubMed Web of Science ®Google Scholar
• Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7(3):497–508.
   PubMedGoogle Scholar
• Suhr O, Danielsson A, Holmgren G, et al. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med. 1994;235(5):479–485.
   PubMed Web of Science ®Google Scholar